X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
OBT076 is a experimental CD205/Ly75-directed ADC which is currently being evaluated in phase 1 clinical trials for the treatment of Adenoid Cystic Carcinoma of the Head and Neck.
Lead Product(s): MEN1309
Therapeutic Area: Oncology Product Name: OBT076
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2024
Details:
OBT620 (BI 764532) is an investigational DLL3/CD3 IgG-like T-cell engager for potential treatment of patients with advanced or metastatic large-cell neuroendocrine carcinoma of the lung.
Lead Product(s): BI 764532
Therapeutic Area: Oncology Product Name: OBT620
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
BI 764532 is an investigational T-cell engager that redirects T cells towards cancer cells expressing the DLL3 protein, which is investigated for the treatment of small cell lung cancer and extrapulmonary neuroendocrine cancers.
Lead Product(s): BI 764532
Therapeutic Area: Oncology Product Name: BI 764532
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
BI 764532 is an investigational T-cell engager that redirects T cells towards cancer cells expressing the DLL3 protein, which is investigated for the treatment of Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancers.
Lead Product(s): BI 764532
Therapeutic Area: Oncology Product Name: BI 764532
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
OBT076 targets the CD205 receptor on tumor cells as well as certain immune suppressive cells in Combination with CPI Balstilimab for patients with advanced solid tumors.
Lead Product(s): MEN1309,Balstilimab
Therapeutic Area: Oncology Product Name: OBT076
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2023
Details:
Under the extended agreement, Boehringer is responsible for the development and commercialization of candidates, including OBT620, that interact with the novel targets identified by OBT’s proprietary OGAP® discovery platform for Boehringer’s immuno-oncology and ADC platforms.
Lead Product(s): OBT620
Therapeutic Area: Oncology Product Name: OBT620
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration May 25, 2023
Details:
The collaboration aims to investigate OBT076, an ADC utilizing an ImmunoGen toxin in patients with Adenoid Cystic Carcinoma (ACC) of the head and neck. The trial will investigate OBT076 as monotherapy and in sequence with balstilimab.
Lead Product(s): MEN1309
Therapeutic Area: Oncology Product Name: OBT076
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: GORTEC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 19, 2023
Details:
Under its Commercial License Agreement with OBT, Genmab will obtain the exclusive right to develop and commercialize novel antibody therapeutics including OBT700R (also known as OBT700), utilizing OBT’s novel, first-in-class IO antibody.
Lead Product(s): OBT700
Therapeutic Area: Oncology Product Name: OBT700R
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Genmab
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 03, 2022
Details:
The antibodies generated by OBT have been coupled with ImmunoGen's proprietary linker-payload technology, each company will have the opportunity to select one or more development programs including lead OBT0227/OBT227, to further develop on its own.
Lead Product(s): OBT227
Therapeutic Area: Oncology Product Name: OBT0227
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Immunogen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 13, 2022
Details:
OBT076 (MEN1309) showed preliminary signs of clinical activity as a monotherapy, with objective responses including long lasting stable disease in six patients, in chemotherapy and checkpoint inhibitor (CPI) refractory patients.
Lead Product(s): MEN1309
Therapeutic Area: Oncology Product Name: OBT076
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
